Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. today reported its financial results for the full year 2022 and provided a business update.
Uncategorized
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer
Vividion Therapeutics, Inc. today announced that Matt Patricelli, Ph.D. has been promoted to Chief Scientific Officer.
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer Read More »
Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To Expand Its Proprietary Technology Platform To Discover Novel Medicines
Pragma Bio developed a first-of-its-kind-map of chemicals designed by nature, housed in humans, and linked to immune-related health outcomes
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.
Nordic Nanovector – Annual and Remuneration Reports Approved
On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2022.
Nordic Nanovector – Annual and Remuneration Reports Approved Read More »
NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023
NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Everest Medicines Announces Signing of an MOU for Strategic Cooperation with Guangdong Academy of Medical Sciences in Renal Diseases
Everest Medicines announced that it has signed an MOU for comprehensive strategic cooperation with Guangdong Academy of Medical Sciences in renal disease research, scientific innovation and translational studies.
Chemours Appoints Denise Dignam President, Titanium Technologies & Chemical Solutions, Gerardo Familiar Named President, Advanced Performance Materials
The Chemours Company, a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, announces the appointment of Denise Dignam as President, Chemours Titanium Technologies and Chemical Solutions, effective April 1, 2023.
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Pionyr and Gilead Sciences, Inc. have mutually agreed to change their 2020 exclusive option agreements.
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement Read More »
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that management will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 8:00 a.m. ET.
Karuna Therapeutics to Present at the Stifel 2023 CNS Days Read More »